| Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients (NCT05222555) | Incyte Corporation | 2022-07-19 |
| A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (NCT05444322) | He Huang | 2022-07-05 |
| Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma (NCT05298293) | Weprom | 2022-07-01 |
| Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (NCT05221645) | University of Southampton | 2022-06-27 |
| Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT05338892) | Regeneron Pharmaceuticals | 2022-06-22 |
| A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) (NCT05144009) | ADC Therapeutics S.A. | 2022-06-21 |
| The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. (NCT05428670) | First Affiliated Hospital of Wenzhou Medical University | 2022-06-15 |
| Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL (NCT05233033) | Kymera Therapeutics, Inc. | 2022-06-13 |
| Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy (NCT05255354) | Adaptive Biotechnologies | 2022-06-01 |
| Genotype-guided Treatment in DLBCL (NCT05351346) | Ruijin Hospital | 2022-06-01 |
| A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma (NCT05121103) | Epizyme, Inc. | 2022-05-31 |
| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma (NCT05326243) | Pell Bio-Med Technology Co., Ltd. | 2022-05-31 |
| B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (NCT05518383) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2022-05-25 |
| Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma (NCT05348213) | Ruijin Hospital | 2022-05-16 |
| A Retrospective Study on Extranodal DLBCL (NCT06549361) | Ruijin Hospital | 2022-05-01 |
| Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia (NCT05281809) | John Lister | 2022-04-19 |
| A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL (NCT05265975) | Antengene Corporation | 2022-04-07 |
| Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL (NCT05269914) | The Affiliated Hospital of Qingdao University | 2022-04-01 |
| First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP (NCT05280626) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-03-25 |
| Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study (NCT04978584) | M.D. Anderson Cancer Center | 2022-03-03 |
| The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years (NCT05179733) | Ruijin Hospital | 2022-03-02 |
| R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse (NCT05257018) | Fudan University | 2022-02-26 |
| Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy (NCT06782854) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2022-02-21 |
| Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells (NCT04911478) | Adicet Therapeutics | 2022-02-14 |
| An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma (NCT05208853) | Zhejiang University | 2022-02-10 |
| Study for Late Assessment of the Safety and Efficacy of Biosimilar Rituximab (NCT04928573) | Libbs Farmacêutica LTDA | 2022-02-08 |
| A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) (NCT04974996) | ADC Therapeutics S.A. | 2022-02-01 |
| A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma (NCT05200312) | The First Affiliated Hospital with Nanjing Medical University | 2022-02-01 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330) | Biomea Fusion Inc. | 2022-01-24 |
| CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia (NCT06081478) | Beijing Tongren Hospital | 2022-01-18 |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (NCT05139017) | Merck Sharp & Dohme LLC | 2022-01-14 |
| ZR-CHOP in DLBCL With Specific Gene Abnormality (NCT05290337) | Fudan University | 2022-01-04 |
| Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma (NCT07443514) | Institute of Oncology Ljubljana | 2022-01-01 |
| A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] (NCT05179603) | Sanofi | 2021-12-07 |
| Imaging Apoptosis for Lymphoma Treatment Response (NCT05048732) | Washington University School of Medicine | 2021-12-06 |
| Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting (NCT05108805) | Vanderbilt-Ingram Cancer Center | 2021-12-02 |
| Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma (NCT04850495) | Yazeed Sawalha | 2021-11-16 |
| Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (NCT04546620) | University Hospital Southampton NHS Foundation Trust | 2021-10-19 |
| Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL (NCT05054426) | Peking Union Medical College Hospital | 2021-10-08 |
| Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. (NCT05645744) | Mustang Bio | 2021-09-29 |
| realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (NCT04981795) | Incyte Corporation | 2021-09-20 |
| The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk (NCT05018520) | Ruijin Hospital | 2021-09-17 |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (NCT05006716) | BeOne Medicines | 2021-09-13 |
| Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line (NCT04670029) | Weprom | 2021-09-08 |
| Copanlisib Plus Venetoclax in R/R DLBCL (NCT04572763) | Dana-Farber Cancer Institute | 2021-09-08 |
| R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden (NCT05040555) | oubai, MD/PhD | 2021-08-30 |
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (NCT04844866) | Miltenyi Biomedicine GmbH | 2021-08-18 |
| Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data (NCT06392763) | Novartis Pharmaceuticals | 2021-08-03 |
| Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma (NCT04491370) | New York Medical College | 2021-08-01 |
| Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS (NCT05022797) | Fundacion CRIS de Investigación para Vencer el Cáncer | 2021-07-19 |
| Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. (NCT04775745) | Newave Pharmaceutical Inc | 2021-07-19 |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma (NCT04739813) | National Cancer Institute (NCI) | 2021-07-09 |
| A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) (NCT04914741) | Peter MacCallum Cancer Centre, Australia | 2021-06-29 |
| Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. (NCT04604067) | Swiss Cancer Institute | 2021-06-25 |
| Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL (NCT04855253) | Masonic Cancer Center, University of Minnesota | 2021-06-09 |
| Chidamide in Patients With Recurrent and Refractory Diffuse Large b (NCT05690191) | Second Affiliated Hospital of Soochow University | 2021-06-01 |
| First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies (NCT04763083) | NovalGen Ltd. | 2021-05-14 |
| Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (NCT04824092) | Incyte Corporation | 2021-05-11 |
| ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma (NCT04517435) | Deepa Jagadeesh | 2021-04-28 |
| Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma (NCT05097443) | Shandong Provincial Hospital | 2021-04-15 |
| A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT07103486) | Novartis Pharmaceuticals | 2021-04-01 |
| A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma (NCT04827004) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-04-01 |
| Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy (NCT04442412) | Fondazione Italiana Linfomi - ETS | 2021-03-23 |
| Immune Responses to COVID-19 Vaccination in Lymphoma Patients (NCT04858568) | University Hospital Southampton NHS Foundation Trust | 2021-03-11 |
| CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML (NCT04787263) | Bambino Gesù Hospital and Research Institute | 2021-03-04 |
| A Phase 1 Study of ADI-001 in B Cell Malignancies (NCT04735471) | Adicet Therapeutics | 2021-03-04 |
| RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies (NCT04844086) | Eden BioCell Ltd. | 2021-03-02 |
| A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (NCT04594642) | AstraZeneca | 2021-03-02 |
| Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma (NCT05164770) | Shandong Provincial Hospital | 2021-03-01 |
| A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04408638) | Hoffmann-La Roche | 2021-02-23 |
| Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL (NCT04502394) | Kartos Therapeutics, Inc. | 2021-02-23 |
| Split-Dose R-CHOP for Older Adults With DLBCL (NCT03943901) | University of Wisconsin, Madison | 2021-02-17 |
| The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell Lymphoma (NCT04695366) | Herlev Hospital | 2021-02-10 |
| Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma (NCT04696692) | Institut Claudius Regaud | 2021-02-09 |
| Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (NCT04512716) | Memorial Sloan Kettering Cancer Center | 2021-02-02 |
| POLA+BR for Relapsed or Refractory DLBCL (NCT04535102) | University of Colorado, Denver | 2021-01-29 |
| A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL） (NCT04610970) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-01-20 |
| CAR T Cell Therapy Related Cardiovascular Outcomes (NCT05130489) | University College London Hospitals | 2021-01-18 |
| A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) (NCT04628494) | Genmab | 2021-01-13 |
| Diet, Physical Activity and Body Composition Changes During R-CHOP (NCT04293900) | George Washington University | 2021-01-01 |
| Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma (NCT04668365) | Henan Cancer Hospital | 2020-12-25 |
| To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (NCT04661007) | Incyte Biosciences Japan GK | 2020-12-15 |
| Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL (NCT04659434) | Qian Wenbin | 2020-12-10 |
| Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity (NCT04503538) | Wake Forest University Health Sciences | 2020-12-01 |
| Study of LUCAR-20S in Patients With R/R NHL (NCT04176913) | The First Affiliated Hospital with Nanjing Medical University | 2020-12-01 |
| Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (NCT04663347) | Genmab | 2020-11-03 |
| A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era (NCT04624971) | Sun Yat-sen University | 2020-11-01 |
| Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years (NCT04622579) | Guangdong Provincial People's Hospital | 2020-10-23 |
| A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (NCT04529772) | Acerta Pharma BV | 2020-10-08 |
| Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma (NCT04544059) | Nanfang Hospital, Southern Medical University | 2020-10-01 |
| Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma (NCT04189952) | University of Miami | 2020-09-22 |
| FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL (NCT04555811) | Masonic Cancer Center, University of Minnesota | 2020-09-22 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (NCT04545762) | C. Babis Andreadis | 2020-09-11 |
| Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL) (NCT04460248) | Ruijin Hospital | 2020-08-26 |
| Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma (NCT04479267) | Barbara Ann Karmanos Cancer Institute | 2020-08-21 |
| Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) (NCT04542824) | Genmab | 2020-08-20 |
| Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (NCT04404283) | Seagen, a wholly owned subsidiary of Pfizer | 2020-08-20 |
| YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial (NCT04500561) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2020-08-20 |
| A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma (NCT04332822) | Nordic Lymphoma Group | 2020-08-19 |
| Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma (NCT04433182) | Fondazione Italiana Linfomi - ETS | 2020-08-18 |